Diurnal Receives Patent Grant from European Patent Office
Diurnal Group has been granted a patent for its hydrocortisone granules in capsules for opening, Alkindi, from the European Patent Office.
Specialty pharmaceutical company, Diurnal Group, has announced the receipt of a patent for its hydrocortisone granules in capsules for opening, Alkindi, from the European Patent Office. The company revealed the news in a Nov. 20, 2020 press release.
Patent EP2780003 for the medical use of Alkindi in the treatment of pediatric patients with adrenal insufficiency, will protect Diurnal’s product in the European market until 2032. Equivalent patents have already been granted in the United Kingdom, Japan, Australia, Israel, South Africa, South Korea, and the United States (for Alkindi Sprinkle).
“With the rapid commercialization of Alkindi being a core focus for Diurnal, we are pleased to receive this patent grant by the European Patent Office,” said Martin Whitaker, CEO of Diurnal, in the press release. “This patent, which builds on our strong global intellectual property position for the product, provides protection in Europe until 2032, supporting our continued commitment to provide Alkindi to pediatric patients suffering from adrenal insufficiency.”
Source: Diurnal
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
